Excell Partners, based in Rochester, NY, made a Series A round investment in ZetaGen Therapeutics Inc.’s (ZetaGen), as a follow-on investment. ZetaGen, a Syracuse, NY-based clinical-stage biopharmaceutical company seeks to stop cancer from growing or spreading by targeting certain biological pathways in the body. This investment will support ZetaGen’s continued R&D efforts and create job opportunities in a low-income community. For more information, visit Excell Partners and ZetaGen Therapeutics.
